Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA: a cancer journal for clinicians. 73:17–48

Linehan WM, Ricketts CJ (2019) The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol 16:539–552

Article  PubMed  Google Scholar 

Koti M, Bivalacqua T, Black PC, Cathomen T, Galsky MD, Gulley JL, Ingersoll MA, Kamat AM, Kassouf W, Siemens DR, Gao J (2023) Adaptive immunity in Genitourinary Cancers. Eur Urol Oncol

Gebrael G, Sahu KK, Agarwal N, Maughan BL (2023) Update on combined immunotherapy for the treatment of advanced renal cell carcinoma. Hum Vaccines Immunotherapeutics 19:2193528

Article  Google Scholar 

Grunewald TG, Butt E (2008) The LIM and SH3 domain protein family: structural proteins or signal transducers or both? Mol Cancer 7:31

Article  PubMed  PubMed Central  Google Scholar 

Katoh M, Katoh M (2003) Identification and characterization of LASP2 gene in silico. Int J Mol Med 12:405–410

PubMed  Google Scholar 

Butt E, Raman D (2018) New Frontiers for the Cytoskeletal protein LASP1. Front Oncol 8:391

Article  PubMed  PubMed Central  Google Scholar 

Sala S, Ampe C (2018) An emerging link between LIM domain proteins and nuclear receptors. Cell Mol Life Sci 75:1959–1971

Article  PubMed  PubMed Central  Google Scholar 

John E, Laskow TC, Buchser WJ, Pitt BR, Basse PH, Butterfield LH, Kalinski P, Lotze MT (2010) Zinc in innate and adaptive tumor immunity. J Translational Med 8:118

Article  Google Scholar 

Stradal TE, Scita G (2006) Protein complexes regulating Arp2/3-mediated actin assembly. Curr Opin Cell Biol 18:4–10

Article  PubMed  Google Scholar 

Bang ML, Chen J (2015) Roles of Nebulin Family members in the heart. Circulation Journal: Official J Japanese Circulation Soc 79:2081–2087

Article  Google Scholar 

Chen L, Wang J, Fan X, Zhang Y, Zhoua M, Li X, Wang L (2021) LASP2 inhibits trophoblast cell migration and invasion in preeclampsia through inactivation of the Wnt/β-catenin signaling pathway. J Recept Signal Transduct Res 41:67–73

Article  PubMed  Google Scholar 

Yang YT, Nie LM, Wei QF, Li WZ (2020) LASP2 functions as a potential prognostic factor and therapeutic target in nasopharyngeal carcinoma. Eur Rev Med Pharmacol Sci 24:9416–9422

PubMed  Google Scholar 

Li J, Hu S, Zhang Z, Qian L, Xue Q, Qu X (2020) LASP2 is downregulated in human liver cancer and contributes to hepatoblastoma cell malignant phenotypes through MAPK/ERK pathway. Biomed Pharmacotherapy = Biomedecine Pharmacotherapie 127:110154

Article  PubMed  Google Scholar 

Zhang X, Cai L, Zhou H, Liu Y, Fan C, Wang L, Li A, Miao Y, Li Q, Qiu X, Wang E (2017) Lasp2 enhances tumor invasion via facilitating phosphorylation of FAK and predicts poor overall survival of non-small cell lung cancer patients. Mol Carcinog 56:2558–2565

Article  PubMed  Google Scholar 

Jiang H, Chen H, Wan P, Chen N (2021) Decreased expression of HADH is related to poor prognosis and immune infiltration in kidney renal clear cell carcinoma. Genomics 113:3556–3564

Article  PubMed  Google Scholar 

Said SS, Ibrahim WN (2023) Cancer Resistance to Immunotherapy: Comprehensive insights with Future perspectives. Pharmaceutics; 15

Zhang Y, Zhang L (2019) Knockdown of LASP2 inhibits the proliferation, migration, and invasion of cervical cancer cells. J Cell Biochem 120:15389–15396

Article  PubMed  Google Scholar 

Zhang Y, Li JH, Yuan QG, Cao G, Yang WB (2019) Upregulation of LASP2 inhibits pancreatic cancer cell migration and invasion through suppressing TGF-β-induced EMT. J Cell Biochem 120:13651–13657

Article  PubMed  Google Scholar 

Yang R, Liao Z, Cai Y, Kong J (2018) LASP2 suppressed malignancy and Wnt/β-catenin signaling pathway activation in bladder cancer. Experimental Therapeutic Med 16:5215–5223

Google Scholar 

Wang B, Zhang L, Zhao L, Zhou R, Ding Y, Li G, Zhao L (2017) LASP2 suppresses colorectal cancer progression through JNK/p38 MAPK pathway meditated epithelial-mesenchymal transition. Cell Communication Signaling: CCS 15:21

Article  PubMed  PubMed Central  Google Scholar 

Zhong F, Lin Y, Zhao L, Yang C, Ye Y, Shen Z Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics. British journal of cancer 2023.

Aggarwal V, Montoya CA, Donnenberg VS, Sant S (2021) Interplay between tumor microenvironment and partial EMT as the driver of tumor progression. iScience 24:102113

Article  PubMed  PubMed Central  Google Scholar 

Choi C, Finlay DK (2021) Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy. Stem Cell Res Ther 12:320

Article  PubMed  PubMed Central  Google Scholar 

Raskov H, Orhan A, Christensen JP, Gögenur I (2021) Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer 124:359–367

Article  PubMed  Google Scholar 

Mittal V (2018) Epithelial mesenchymal transition in Tumor Metastasis. Annu Rev Pathol 13:395–412

Article  PubMed  Google Scholar 

Deng XA, Norris A, Panaviene Z, Moncman CL (2008) Ectopic expression of LIM-nebulette (LASP2) reveals roles in cell migration and spreading. Cell Motil Cytoskeleton 65:827–840

Article  PubMed  PubMed Central  Google Scholar 

Romeo E, Caserta CA, Rumio C, Marcucci F (2019) The vicious cross-talk between Tumor cells with an EMT phenotype and cells of the Immune System. Cells; 8

Dongre A, Weinberg RA (2019) New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 20:69–84

Article  PubMed  Google Scholar